Insulin glulisine - The potential for improved glycaemic control

British Journal of Diabetes and Vascular Disease

Volumn 7, Issue 2, 2007, Pages 60-66

  Owens, David R ^a  

^a LLANDOUGH HOSPITAL   (United Kingdom)

Author keywords

Insulin glulisine; Pharmacodynamics; Pharmacokinetics; Type 1 diabetes; Type 2 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; ORAL ANTIDIABETIC AGENT; POLYSORBATE 20;

AREA UNDER THE CURVE; CATHETER OCCLUSION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DIABETIC ANGIOPATHY; DOSE KIDNEY FUNCTION RELATION; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG STABILITY; EVIDENCE BASED MEDICINE; GENETIC ENGINEERING; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INJECTION SITE; INJECTION SITE REACTION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN HYPOGLYCEMIA; INSULIN RELEASE; LONG TERM CARE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATIENT COMPLIANCE; PHARMACODYNAMICS; REVIEW; RISK REDUCTION; SIDE EFFECT; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; WEIGHT GAIN;

EID: 34249028976     PISSN: 14746514     EISSN: None     Source Type: Journal    
DOI: 10.1177/14746514070070020301     Document Type: Review

References (35)

1. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
2. The Diabetes Control and Complications (DCCT) Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
3. The DCCT/EDIC Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-53.
4. Stevens RJ, Coleman RL, Adler Al et al. Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes. UKPDS 66. Diabetes Care 2004;27:201-07.
5. Department of Health. National Service Framework for Diabetes: Delivery Strategy. 2003.
6. National Institute for Clinical Excellence. Management of type 2 diabetes: Management of blood glucose (inherited clinical guideline G). 2002.
7. National Health Service Confederation and British Medical Association. The new GMS Contract. 2003; http://www.nhsemployers.org/primary/ primary-902.cfm.
8. Bohannon NJ. Optimizing insulin regimens in type 1 diabetes. How to help patients get control of their life. Postgrad Med 2003; 113:39-42,45-8,54.
9. Barnett AH, Capaldi B, Davies-Lyons M et al. Expert opinion statement on the use of insulin therapy in patients with Type 2 diabetes in primary care. Practical Diabetes International 2003; 20:97-102.
10. Brange J, Owens DR, Kang S et al. Monomeric insulins and their experimental and clinical implications. Diabetes Care 1990; 13:923-54.
11. Electronic Medicines Compendium. 2006; http://emc.medicines.org.uk
12. Becker RH. Insulin Glulisine complementing basal insulins: a review of structure and activity. Diabetes Technol Ther 2007 9:109-21.
13. Becker RH, Frick AD, Burger F et al. Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects. Exp Clin Endocrinol Diabetes 2005; 113:435-43.
14. Luzio S, Dunseath G, Peter R. Comparison of the pharmacokinetics and pharmacodynamics of biphasic insulin aspart and insulin glargine in people with type 2 diabetes. Diabetologia 2006; 49:1163-8.
15. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients. Diabetes Care 2003; 26:881-5.
16. DECODE Study Group EDEG. Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care 2003;26:688-96.
17. Ceriello A, Hanefeld M, Leiter L et al. Postprandial glucose regulation and diabetic complications. Arch Intern Med 2004; 164:2090-5.
18. Feher MD, Bailey CJ. Reclassifying insulins. Br J Diabetes Vasc Dis 2004;4:39-42.
19. Overmann H, Heinemann L. Injection-meal interval: recommendations of diabetologists and how patients handle it. Diabetes Res Clin Pract 1999;43:137-42.
20. Betz JL. Fast-acting human insulin analogs: a promising innovation in diabetes care. Diabetes Educ 1995;21:195-200.
21. Owens DR, Zinman B, Bolli GB. Insulins today and beyond. Lancet 2001;358:739-46.
22. Summary of Product Characteristics. emc.medicines.org.uk/
23. Becker RH, Frick AD, Burger F et al. A comparison of the steady-state pharmacokinetics and pharmacodynamics of a novel rapid-acting insulin analog, insulin glulisine, and regular human insulin in healthy volunteers using the euglycemic clamp technique. Exp Clin Endocrinol Diabetes 2005;113:292-7.
24. Becker RHA, Frick AD, Wessels DH et al. Pharmacodynamics and pharmacokinetics of a new rapidly-acting insulin analog, insulin glulisine. Diabetes 2003;52(suppl 1)pA110(Abstract 471-P).
25. Brange J, Langkjoer L. Insulin structure and stability. Pharm Biotechnol 1993;5:315-50.
26. Hanaire-Broutin H, Schumicki DM, Hoogma RPLM et al. Safety of insulin glulisine compared with insulin aspart administered by continuous subcutaneous insulin infusion (CSII). ADA Conference 2004.
27. Frick A, Becker R, Wessels D et al. Pharmacokinetic and glucodynamic profiles of insulin glulisine following subcutaneous administration at various injection sites. Diabetes 2003; 52(suppl 1)A118 (Abstract 511-P).
28. Frick A, Becker R. Predictable and consistent insulin glulisine pharmacokinetics in various populations - an across phase study analysis. Diabetes 2005;54(suppl 11):pA518(Abstract 2154).
29. Holmes G, Galitz L, Lyness W. Pharmacokinetics of insulin aspart in obesity, renal impairment, or hepatic impairment. Br J Clin Pharmacol 2005;60:469-76.
30. Danne T, Becker RH, Heise T et al. Pharmacokinetics, prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetes. Diabetes Care 2005; 28:2100-05.
31. Jaros M, Martinek R, Piechatzek R et al. Pharmacokinetics of insulin glulisine in non-diabetic renally impaired patients. ADA Conference 2004.
32. Nosek L, Becker R, Frick A et al. Prandial Blood Glucose Control with Pre- and Post-Meal Insulin Glulisine Versus Regular Human Insulin. Diabetes 2004;53(suppl 2):A139(Abstract 588-P).
33. Garg S, Rosenstock J, Ways K. Optimized basal-bolus insulin regimens in Type 1 diabetes: insulin glulisine versus regular human insulin in combination with basal insulin glargine. Endocr Pract 2005; 11:11-17.
34. Garg S, Chen Y, Souhami E. Reduction in insulin dose and body weight with pre- and post-meal insulin glulisine (GLU) versus regular human insulin (RHI) in patients with type 1 diabetes. Diabetes 2005; 54(suppl 1):A144 (Abstract 581-P).
35. Dailey G, Rosenstock J, Moses R. Insulin glulisine provides improved glycaemic control in patients with type 2 diabetes. Diabetes Care 2004;27:2363-8.